Comparative Pharmacology
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus IBUPROFEN.
ADVIL CONGESTION RELIEF vs Ibuprofen
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
None Documented
None Documented
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Clinical Note
moderateIbuprofen + Gatifloxacin
"Ibuprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIbuprofen + Rosoxacin
"Ibuprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIbuprofen + Levofloxacin
"Ibuprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIbuprofen + Trovafloxacin
"Ibuprofen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Category C
Category D/X
NSAID/Decongestant Combination
NSAID